骨髓增生异常综合征：揭开谜团。
MDS: unraveling the mystery.
机构信息
Duke Cancer Institute.
出版信息
Blood. 2012 Dec 13;120(25):4906-8. doi: 10.1182/blood-2012-09-452755.
PMID:23243154
Abstract
In this issue of Blood, Sekeres et al report a phase 2 study of lenalidomide and azacitidine for higher risk myelodysplastic syndromes (MDS). High overall response and duration of response supports the concept of combination, multitargeted approaches rather than traditional chemotherapeutics for this disease.
摘要
在本期《Blood》中，Sekeres 等人报告了来那度胺联合阿扎胞苷治疗高危骨髓增生异常综合征（MDS）的 2 期研究结果。总体反应率和缓解持续时间较高，支持针对该疾病采用联合、多靶点治疗方法而非传统化疗药物的理念。
Zotero 插件